Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease by Meissner, H.C. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
0066-4804/99/$04.0010
May 1999, p. 1183–1188 Vol. 43, No. 5
Copyright © 1999, American Society for Microbiology. All Rights Reserved.
Safety and Pharmacokinetics of an Intramuscular Monoclonal
Antibody (SB 209763) against Respiratory Syncytial Virus
(RSV) in Infants and Young Children at Risk for
Severe RSV Disease
H. CODY MEISSNER,1* JESSIE R. GROOTHUIS,2 WILLIAM J. RODRIGUEZ,3 ROBERT C. WELLIVER,4
GEOFF HOGG,5 PETER H. GRAY,6 RICHARD LOH,7 ERIC A. F. SIMOES,8 PETER SLY,7
ANN K. MILLER,9 ALICE I. NICHOLS,9† DIANE K. JORKASKY,9
DANIEL E. EVERITT,9 AND KATHLEEN A. THOMPSON9
Department of Pediatrics, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts
021111; Ross Products Division, Columbus, Ohio 432152; Department of Pediatrics, National Children’s Medical
Center, Washington, D.C. 200103; Department of Pediatrics, Children’s Hospital of Buffalo, Buffalo, New York 422224;
Royal Children’s Hospital, Parkville, Victoria,5 The Mater Misercordias Public Hospitals, South Brisbane, Queensland,6
and Princess Margaret Hospital, Subiaco, Perth, Western Australia,7 Australia; Department of Pediatrics,
University of Colorado School of Medicine and Children’s Hospital, Denver, Colorado 802188;
and SmithKline Beecham, Philadelphia, Pennsylvania 191049
Received 1 June 1998/Returned for modification 5 September 1998/Accepted 25 February 1999
We conducted a multicenter, double-blind, placebo-controlled, randomized trial of a humanized monoclonal
antibody against a respiratory syncytial virus (RSV) fusion protein (SB 209763) to evaluate its safety, phar-
macokinetics, and fusion inhibition and neutralization titers. Forty-three infants who were either delivered
prematurely (<35 weeks’ gestation) or exhibited bronchopulmonary dysplasia were administered either single
or repeat (two doses, 8 weeks apart) intramuscular injections of SB 209763 at a concentration of 0.25, 1.25, 5.0,
or 10.0 mg/kg or of a placebo. Four of 229 adverse events were considered related to the study drug, including
purpura (n 5 3) and thrombocytosis (n 5 1). No subject developed a detectable level of anti-SB 209763
antibody. Approximately 1 week after administration of the second dose of SB 209763 at 10 mg/kg, the mean
plasma concentration (n 5 9) was 68.5 mg/ml. The terminal half-life (T1/2) determined by noncompartmental
analysis ranged from 22 to 50 days. The population pharmacokinetics for SB 209763 following intramuscular
administration was appropriately described by a one-compartment model with first-order input and elimina-
tion. Higher values for clearance and volume of distribution at steady state were observed for younger patients,
with values decreasing to 0.143 (ml/h)/kg and 161 mL/kg, respectively, by a mean age of 298 days (;10 months).
The mean T1/2 of SB 209763 for the study population was 32.5 days. No other factor (dose, weight, gender, race,
premature birth, or bronchopulmonary dysplasia) was observed to alter the population pharmacokinetics of
SB 209763 in this study of infants and young children. The mean neutralization titer on day 6 was 286, and the
mean fusion inhibition titer was 36. At least 57% of subjects dosed at 1.25 to 10.0 mg of SB 209763 per kg of
body weight who were seronegative at baseline experienced a fourfold or greater increase in fusion inhibition
titer. Nine RSV infections were documented during the 16-week course of the study; the numbers of RSV
infections were similar for the different regimens, including the placebo. The doses of SB 209763 studied may
have been insufficient to confer protection against RSV lower respiratory tract disease; these results suggest
that additional trials using higher doses of monoclonal antibody for immunoprophylaxis should be considered.
Respiratory syncytial virus (RSV) remains one of the most
important infectious causes of hospitalization of infants and
young children (8). Seasonal outbreaks of RSV disease result
in infection in over 90% of children by 2 years of age. The
outcome varies from a mild upper respiratory tract illness in
approximately 75% of infected infants and children to a severe,
life-threatening disease in a small percentage of infected pa-
tients. Infants at particular risk of severe disease include pre-
maturely born children, children born with congenital heart
disease, and children with chronic lung disease, particularly
bronchopulmonary dysplasia (BPD) (10).
Despite the importance of RSV as a pathogen in the pedi-
atric age group, options for treatment and prevention of RSV
disease are limited. Active immunization to prevent severe
RSV disease has not yet proven successful (7). Two clinical
trials with a polyclonal, hyperimmune RSV globulin have dem-
onstrated safety and efficacy for prophylaxis in carefully se-
lected children at increased risk for severe RSV infection (6,
13). The results of these clinical trials led to Food and Drug
Administration licensure of this RSV antibody-enriched im-
mune globulin in January 1996.
A second-generation product for immunoprophylaxis
against RSV disease is a monoclonal antibody directed against
a highly immunogenic RSV surface glycoprotein (12, 15).
Monoclonal antibodies to the fusion protein have been shown
to be effective in preventing RSV infection in animal models
(3, 17–19) and in humans (9). During the 1995-1996 respiratory
virus season, a multicenter, double-blind, placebo-controlled,
* Corresponding author. Mailing address: New England Medical
Center, Box 321, 750 Washington St., Boston, MA 02111. Phone: (617)
636-5227. Fax: (617) 636-4300. E-mail: cmeissner@es.nemc.org.
† Present address: Hawthorne Research and Consulting, King of
Prussia, PA 19406.
1183
 o
n
 O
ctober 21, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
randomized trial was conducted with SB 209763, a humanized
murine monoclonal antibody directed against the RSV fusion
glycoprotein. The primary objectives of this phase I trial were
to evaluate the safety and pharmacokinetics of single and re-
peat intramuscular (i.m.) doses of SB 209763 in a pediatric
population at risk for severe RSV disease. The secondary ob-
jectives included measurement of fusion inhibition titers and
neutralization titers and assessment of anti-idiotypic anti-SB
209763 antibodies.
(This study was presented in part at the 37th Interscience
Conference on Antimicrobial Agents and Chemotherapy, To-
ronto, Ontario, Canada, 28 September to 1 October 1997.)
MATERIALS AND METHODS
Patients. Infants and young children less than 37 months of age were eligible
for enrollment at one of the seven participating sites if they were born prema-
turely (#35 weeks), with a chronological age of #6 months, and/or had a history
of BPD. Eligible subjects were required to have a life expectancy of at least 6
months. The protocol was approved by the institutional review board at each site,
and informed consent was obtained from all participating families. Exclusion
criteria included known preexisting heart, liver, or renal disease; a recognized
immune system abnormality; severe respiratory illness requiring assisted venti-
lation; or previous gamma globulin infusion.
Randomization. Participants were randomly assigned to one of four monoclo-
nal antibody dosage groups (0.25, 1.25, 5.0, or 10.0 mg of SB 209763 per kg of
body weight) or to a placebo group according to a randomization schedule
provided by SmithKline Beecham. Each dosage group included at least eight
subjects; within each dosage group, at least six infants received SB 209763 at the
first administration while at least two subjects received the placebo (Table 1).
Eight weeks after administration of the first dose, a second i.m. injection was
given. Subjects who were randomized to received the monoclonal antibody ini-
tially received a repeat dose identical to the initial dose. Subjects who initially
received the placebo were crossed over and received SB 209763 at a dosage
consistent with that for the group to which they were initially assigned.
The 8-week dosing interval was identical to the dosing interval examined in an
earlier study of adults (unpublished data). Results from this study and an addi-
tional trial involving adults demonstrated that plasma levels of SB 209763 remain
above 10 mg/ml 8 weeks after i.m. administration for at least some of the dosages
used in the present study (4). This concentration has been associated with
protection in murine and rat models of RSV infection in vivo (19).
Study drug. SB 209763 lyophilate (lot no. U-94045), reconstituted with sterile
water to a concentration of 45 mg/ml, and a placebo (a solution containing all
components of the active preparation except SB 209763) were used in this study.
Doses of 0.25 and 1.25 mg of SB 209763/kg were administered as single i.m.
injections into one thigh muscle. Doses of 5.0 and 10.0 mg/kg were divided and
administered as separate injections into each thigh muscle to maintain reason-
able injection volumes. Placebo subjects were injected with a volume of placebo
equivalent to the volume of active drug that would have been received by a
subject of identical weight assigned to that dosage group. At the highest dose, a
volume of 0.22 ml of either active drug or placebo per kg was administered.
Higher doses of SB 209763 were not administered within a randomization
regimen until at least three subjects within the regimen’s dosage group had
received a lower dose and were evaluated through 24 h postdosing (thus ensuring
that at least two of the three dosed individuals received the active drug). This
evaluation included an assessment of the results of laboratory studies for patient
safety, conducted 24 h after injection of the study medication. The following
laboratory tests were performed: complete blood count; differential blood count;
platelet count; determination of alanine aminotransferase, aspartate aminotrans-
ferase, total bilirubin, alkaline phosphatase, and creatinine levels in serum; and
urinalysis. Dose escalation was halted and reevaluated in a consultation with the
study sponsor upon occurrence of a serious adverse response.
Safety parameters. Screening visits included a medical history and physical
examination. A physical examination was performed and blood and urine sam-
ples were collected for laboratory tests for determination of patient safety prior
to administration of each dose of the study medication. Blood and urine samples
were also obtained for laboratory testing at 24 h and 2 weeks after administration
of the first dose and at 2 weeks after administration of the second dose of the
study medication. A physical examination was also performed at the 2-week-
postdose visit. Injection sites were examined for local reactions at approximately
5 min, 2 h, and between 4 and 7 days after each injection. Vital signs were
measured prior to and at 15, 30, 45, 60 and 120 min following administration of
each dose of the study drug.
Blood samples were obtained prior to and approximately 6 days and 2 and 8
weeks following administration of each dose for assessment of the presence of
anti-SB 209763 antibodies. Plasma was analyzed for anti-SB 209763 antibodies by
sandwich enzyme-linked immunosorbent assay. Serial dilutions of plasma sam-
ples were added to microtiter plates coated with SB 209763. Anti-SB 209763
antibodies present in plasma were allowed to bind; the sandwiched anti-SB
209763 was detected by binding of biotin-labeled SB 209763 followed by the use
of an avidin-biotinylated alkaline phosphatase system. The positive controls, a
bovine monoclonal anti-idiotypic antibody and a rabbit polyclonal anti-SB
209763 antibody, were included in each assay.
Subjects were monitored during the RSV season for the presence of RSV
disease symptoms through biweekly telephone contacts. If a subject developed
respiratory symptoms, attempts were made to obtain a nasopharyngeal aspirate,
which was tested for the presence of RSV by antigen detection assay. Samples
testing positive were transported to a central processing laboratory for RSV
culture and titer determination. Pairs of tubes of Hep2 cells (in 1.5 ml of basal
medium [Eagle minimal medium supplemented with 2% fetal calf serum, 2%
L-glutamine, and 1% penicillin-streptomycin-Fungizone]) were each inoculated
with 0.2 ml of 100 to 1026 dilutions of the nasopharyngeal aspirate specimen. The
inoculated cells were then incubated at 34°C for 3 weeks and observed three
times per week for development of cytopathic effects. The maintenance medium
was changed two times per week. Observed virus titers were expressed as 50%
tissue culture infective doses per milliliter.
Pharmacokinetic parameters. For analysis of plasma SB 209763 concentra-
tions, venous blood samples were collected in sodium citrate tubes prior to
administration of the first dose and at approximately 24 h, 6 days, and 2 and 8
weeks after the first dose of study medication was administered. The 8-week
sample was drawn just prior to administration of the second dose. Blood samples
were also drawn at approximately 6 days and 2 and 8 weeks after administration
of the second dose of the study medication.
Plasma SB 209763 concentrations were quantified by an enzyme-linked im-
munosorbent assay based on the simultaneous binding of SB 209763 to two
bovine anti-idiotypic monoclonal antibodies, B11 and B12 (3). Briefly, SB 209763
was captured from plasma in a microtiter plate to which B11 had been bound.
The B11-SB 209763 complex was then probed with biotinylated B12, forming a
sandwich which was detected with horseradish peroxidase-conjugated streptavi-
din. The lower limit of detection of SB 209763 in 10% (vol/vol) phosphate saline
buffer was 0.030 mg/ml. A low predose response was noted in one patient in the
1.25-mg/kg group. However, this value had no effect on the data analysis, since
all postdosing SB 209763 concentrations in this patient were at least 30-fold
higher than the predose level. Typical within- and between-run precision values
(coefficients of variation) for this assay were 2.8 to 8.4% and 0.8 to 12.9%,
respectively. Typical average accuracy values were 94 to 105%.
Concentration-time data for each subject in each dose group were analyzed by
noncompartmental methods. The area under the plasma concentration-time
curve from immediately predose (time zero) to the last quantifiable concentra-
tion (AUC0–t), the peak concentration of SB 209763 (Cmax), and the apparent
terminal elimination phase half-life (T1/2) were determined for both the first and
second doses of SB 209763. The AUC for the first dose was calculated by using
samples obtained prior to administration of the second dose. The AUC following
administration of the second dose (the sum of the AUC for the second dose plus
that remaining from the first dose) was calculated by using blood samples ob-
tained immediately before administration of the second dose as well as samples
obtained at 6 days and at 2 and 8 weeks after administration of the second dose.
The apparent terminal elimination phase rate constant, lz, was derived from the
log-linear disposition phase of the concentration-time curve by least-squares
regression analysis with visual inspection of the data to determine the appropri-
ate number of data points for the calculation of lz. At least three points in the
terminal elimination phase were required for calculation of lz. The AUC0–t was
calculated by using the linear trapezoidal rule for each incremental trapezoid and
the log trapezoidal rule for each decremental trapezoid. The T1/2 was calculated
as ln 2/lz.
The plasma concentration-time data were further analyzed by using nonlinear
mixed-effect modeling as implemented in the NONMEM computer program (1,
2). Based on a visual examination of these data and data from a previous study
of healthy adults, a one-compartment model with first-order input and elimina-
tion was used to describe the data. This model was parameterized in terms of the
apparent clearance (CL/F), the volume of distribution at steady state (VSS/F),
TABLE 1. Randomization of infants
Inoculum (dose, mg/kg)
No. of subjects
First Second
SB 209763 (0.25) SB 209763 (0.25) 6
SB 209763 (1.25) SB 209763 (1.25) 9
SB 209763 (5.0) SB 209763 (5.0) 8
SB 209763 (10.0) SB 209763 (10.0) 10
Placebo SB 209763 (0.25) 2
Placebo SB 209763 (1.25) 2
Placebo SB 209763 (5.0) 3
Placebo SB 209763 (10.0) 3a
a Includes one subject who was withdrawn from the study prior to receiving the
second dose.
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and the absorption rate (ka) following i.m. administration. The effects of patient
demographics and other factors (dose, age, weight, gender, race, premature
birth, and BPD on the pharmacokinetic parameters CL/F and Vss/F were as-
sessed to determine whether these factors should be retained in the final model.
To examine the potential effect of these factors on the pharmacokinetics of SB
209763, the value of ka was fixed at 0.0469 liters/h.
The primary consideration in selecting which model to use in analyzing the
data (including selection of the factors to be included in the model) involved a
statistically significant change in the objective function as implemented by Beal
and Sheiner (2). For hierarchical models, a difference of 8 in the objective
function was assumed to be significant at the 95% level when there was a change
of 1 degree of freedom. Nonhierarchical models were assessed by direct com-
parison of the log likelihood values. The following were also crucial to the
selection of a model: (i) assessment of the weighted residual plots showing any
variability as featureless random noise; (ii) increased precision in parameter
estimates, resulting in smaller values for standard error; and (iii) reduction in
estimates of interindividual variances.
Pharmacodynamic parameters. Venous blood samples for analysis of fusion
inhibition and plasma neutralization antibody titers were obtained prior to ad-
ministration of each dose and at approximately 6 days and 2 and 8 weeks after
administration of SB 209763 or the placebo. In vitro microneutralization assays
were used to measure the ability of SB 209763 to inhibit the growth of RSV (4).
Fusion inhibition and plasma neutralization titers were expressed as the recip-
rocal of the dilution which caused a 50% reduction in the optical density at 450
nm based on regression analysis of the dose titration.
RESULTS
Enrollment. Forty-three infants and children were enrolled
in this study (11 premature infants without BPD and 32 infants
with BPD). The subjects ranged in age from 8 days to 33
months and weighted between 1.1 and 15.5 kg (mean, 5.3 kg)
at the time of enrollment. The racial demographics were as
follows: 74% white, 12% black, 12% Oriental, and 2% other.
Forty-two subjects completed the study. One subject was with-
drawn due to noncompliance with the follow-up protocol after
receiving one 10-mg/kg dose of SB 209763. This subject was
included in the analysis as if the 10-mg/kg treatment regimen
had been completed. The number of subjects who received
each treatment regimen is shown in Table 1. The patient de-
mographics as a function of dosage group are shown in Table
2. Although it is difficult to assess homogeneity across dosage
groups given the relatively small sample size, it appears that
the groups were fairly well balanced in terms of mean age and
weight. The racial compositions of the groups were also rela-
tively balanced; participants in all four dosage groups were
predominantly white. The gender distributions of the three
lowest-dosage groups were similar, with more females being
enrolled than males; the highest-dosage group was skewed in
the opposite direction. The majority of subjects in each group
had chronic lung disease (BPD).
Safety results. Single and repeat doses of 0.25 to 10.0 mg of
SB 209763 per kg were safe and well tolerated. There were no
deaths during the study. There were 229 adverse events re-
ported for 41 subjects over the 16 weeks following treatment
with the study medication. Thirty-seven adverse events oc-
curred in 10 subjects who received the placebo, and 192 were
reported in 35 subjects who received SB 209763. Most were
mild to moderate in severity. Four adverse events were con-
sidered by the investigators to be related to the study drug.
These included three episodes of mild to moderate purpura,
which occurred in two subjects, and thrombocytosis, which
occurred in one subject. The purpura developed at the site of
blood sampling. All adverse events had resolved by the end of
the study surveillance period. Nineteen laboratory test values
were considered clinically relevant by the investigator. Two of
these, granulocytopenia and thrombocytosis, were considered
to be related to the study medication. The administration of
the study drug was not altered in any patient due to side effects.
Erythema or induration at the injection site was observed at
30% of placebo injection sites and at 48% of SB 209763 injec-
tion sites at 5 min postadministration. Most reactions consisted
of erythema without induration. No adverse reactions were
evident in placebo recipients after 5 min. Eight percent of SB
209763 injection sites continued to show a response at 2 h
postadministration. No reactions were evident at the final
scheduled assessment (between 4 and 7 days postadministra-
tion). These reactions were not reported to be associated with
obvious pain or discomfort and were not considered by the
investigators to be clinically relevant.
None of the subjects’ plasma samples tested positive for
anti-SB 209763 antibodies.
RSV infection. Sixty-five episodes of respiratory illness oc-
curred. During 40 of these episodes, nasopharyngeal speci-
mens were obtained, and RSV was recovered from nine spec-
imens, as shown in Table 3. Although there were fewer RSV
infections in the group receiving SB 209763 at 10 mg/kg (1 of
22) than in the placebo group (2 of 10), the difference was not
statistically significant (P 5 0.20).
Pharmacokinetic evaluation. Following noncompartmental
analysis of the SB 209763 concentration data, Cmax values and
total exposure (as indicated by the AUC) of SB 209763 fol-
lowing i.m. administration increased with increasing dosages of
SB 209763 (Table 4). All subjects had quantifiable concentra-
tions of SB 209763 at the last sampling times for the first and
second doses of SB 209763. The T1/2 was calculated only if at
least three time-concentration values were present in the ter-
minal phase. This resulted in the T1/2 being estimated for 21 of
75 concentration-time profiles derived from 43 subjects, rang-
ing from 22 to 50 days. Concentrations of SB 209763 were
available on days 1 and 6 after the first dose of SB 209763 was
administered in 19 of the 43 subjects. All 19 of the subjects had
higher concentrations on day 6 than on day 1. Mean concen-
trations in specimens obtained on day 56 (6 7 days), as shown
in Table 4, ranged from 0.50 to 21.1 mg/ml for dosages of 0.25
TABLE 2. Patient demographics by dosage group
Enrollment status
Dose (mg/kg)
0.25 1.25 5.0 10.0
Age at time of enrollment
Mean (months) 6.0 9.8 9.8 5.4
Range (months) 4 to 11 0.75 to 30 0.25 to 33 0.75 to 13
Mean weight at time of
enrollment (kg)
5.3 6.3 5.1 4.5
Male/female ratio 3/5 5/6 3/8 10/3
Race (white/black/other) 7/1/0 7/2/2 7/1/3 11/1/1
RSV risk factor(s)
Prematurity 2 3 4 2
BPD plus prematurity 5 2 2 6
BPD alone 1 6 5 5
TABLE 3. Frequency of RSV-positive episodes by dosage
Group No. infected/total (%) p valuea 95% CIb
Placebo 2/10 (20%)
SB 209763
0.25 mg/kg 2/14 (14%) 0.72 0.07–5.75
1.25 mg/kg 2/20 (10%) 0.46 0.05–3.74
5.0 mg/kg 2/19 (11%) 0.49 0.05–3.97
10.0 mg/kg 1/22 (5%) 0.20 0.01–2.40
a Logistic regression analysis was used to compare each group with the placebo
group.
b CI, confidence interval.
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to 10 mg/kg. Mean plasma SB 209763 concentrations following
single and repeat i.m. doses are shown in Fig. 1.
Based on NONMEM analysis, the SB 209763 plasma con-
centration-time data in this patient population were ade-
quately described by a one-compartment model with first-or-
der input. A covariate evaluation showed that the CL/F and
VSS/F values were higher for younger patients, with values
decreasing with increasing age to 0.143 (ml/h)/kg and 161 ml/
kg, respectively, by a mean age of 298 days (;10 months). The
corresponding T1/2 for a mean age of 298 days was 32.5 days.
The relationship between age and CL/F was described as fol-
lows: CL/F 5 0.143 z (age/298)20.316. For VSS/F, the model
which included age was described as follows: VSS/F 5 161 z
(age/298)20.306. The exponential equations permitted predic-
tions for CL/F and VSS/F to increase for newborns through the
age of 298 days and to level off as the age increased beyond 298
days. Between-subject variabilities described by coefficients of
variation for CL/F and VSS/F were estimated to be 34 and 33%,
respectively. No other factor (dose, weight, gender, race, pre-
mature birth, or BPD) was observed to alter the population
pharmacokinetics of SB 209763 in this study of infants and
young children. Dose linearity is supported by the fact that
changes in CL/F and VSS/F were not related to dose amounts.
Pharmacodynamic evaluation. The mean and median neu-
tralization and fusion inhibition antibody titers on day 6 are
shown, in comparison to the corresponding predose titers, in
Table 5. Increases in most of the titers were observed for
recipients of each of the four dosing regimens. In the 10 pla-
cebo recipients, median titers did not significantly change be-
tween predose and 6-day-postdose specimens. Among infants
who received a dose of 10 mg/kg, there was typically a two- to
fourfold increase over predose titers. The wide range of pre-
TABLE 4. Pharmacokinetic parameters for SB 209763 after single and repeat i.m. doses
Parameter
Mean value 6 SD (n) at a dose of (mg/kg)a:
Single or repeat
administration 0.25 1.25 5.0 10.0
Cmax (mg/ml) Single 1.77 6 0.54 (8) 6.84 6 2.07 (11) 22.6 6 14.0 (11) 40.9 6 12.6 (13)
Repeat 2.33 6 0.65 (6) 8.51 6 3.27 (9) 28.0 6 14.0 (8) 68.5 6 18.0 (9)
Concn, day 56 (mg/ml) Single 0.50 6 0.24 (8) 2.50 6 0.94 (9) 8.48 6 5.97 (10) 14.4 6 6.52 (11)
Repeat 0.77 6 0.21 (6) 2.85 6 1.28 (7) 11.42 6 6.18 (6) 21.1 6 10.6 (8)
AUC0–t (mg z h/ml) Single 1,313 6 384 (8) 5,611 6 1,655 (11) 17,197 6 10,912 (11) 35,794 6 10,098 (13)
Repeat 1,829 6 454 (6) 7,166 6 2,556 (9) 23,059 6 14,078 (7) 57,363 6 10,483 (9)
a Values are provided for concentrations obtained on day 56 (6 1 week). Parenthetic.
FIG. 1. Mean SB 209763 concentrations, 6 standard deviations, versus time for subjects receiving doses of 0.25 mg/kg (E), 1.25 mg/kg (h), 5 mg/kg (), or 10 mg/kg
({).
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dose neutralization and fusion inhibition antibody titers among
infants in different dosing groups explains at least some of the
variation in peak titers after dosing.
To further evaluate the change in the levels of both neutral-
izing antibodies and fusion inhibition antibodies, the same data
were analyzed as ratios of the concentrations on day 6 to the
predose titers (Table 6). This analysis also shows the difference
between predose and day 6 concentrations in those subjects
who were seronegative prior to the first dose. Although the
number of SB 209763 recipients who were seronegative before
administration of the first dose was small in each category, the
majority of seronegative subjects who received SB 209763 at a
dose of 1.25 mg/kg or higher demonstrated more than a four-
fold increase in neutralizing and fusion inhibition antibody
titers on day 6.
DISCUSSION
In the absence of a safe and effective vaccine, passive im-
munoprophylaxis holds the greatest promise for the prevention
of severe RSV illness in high-risk children. Studies have shown
that immunoprophylaxis with a polyclonal, hyperimmune RSV
globulin is effective in attenuating RSV disease both in animal
models and in high-risk infants and children. However, there
are several disadvantages to this product, including the need
for intravenous administration, the fluid volume associated
with its administration, the less-than-complete protection
against RSV disease achieved, and the issue of safety in chil-
dren with cyanotic heart disease (11). An effective monoclonal
antibody can be administered i.m., thereby avoiding many of
these difficulties.
Monoclonal antibodies of purely murine origin have not
been widely used in clinical trials due to concerns with regard
to the development of anti-murine antibodies. Substitution of
human sequences for the murine sequences within the non-
antigen-binding region of the molecule results in a lower de-
gree of immunogenicity relative to that of unmodified murine
monoclonal antibodies. In the present trial, single and repeat
doses of 0.25 to 10.0 mg of SB 209763, a humanized murine
monoclonal antibody against the RSV fusion protein, per kg
were safe and well tolerated when administered i.m. to high-
risk infants. Evaluation of the local and systemic anti-SB
209763 immune response failed to reveal evidence of an im-
mune reaction against this humanized antibody. These results
are similar to those of previous studies of healthy male subjects
TABLE 5. Neutralization and fusion inhibition antibody titers
Titer type
Antibody titer for study group administered:
SB 20973 at dose of:
Placebo
(n 5 10)10 mg/kg
(n 5 11)
5 mg/kg
(n 5 11)
1.25 mg/kg
(n 5 9)
0.25 mg/kg
(n 5 7)
Neutralization titer
Mean (SD)
Predose 155 (66) 228 (89) 704 (338) 278 (119) 1,255 (984)
Day 6 postdose 286 (89) 375 (102) 508 (185) 304 (127) 1,146 (985)
Median (range)
Predose 67 (2–675) 109 (2–877) 234 (2–3,098) 234 (2–855) 129 (2–10,000)
Day 6 postdose 131 (32–961) 242 (32–1,130) 310 (59–1,890) 132 (11–770) 104 (2–10,000)
Fusion titer
Mean (SD)
Predose 11 (4) 22 (13) 35 (19) 52 (25) 26 (15)
Day 6 postdose 36 (9) 96 (41) 76 (33) 72 (33) 12 (5)
Median (range)
Predose 2 (2–37) 2 (2–137) 18 (2–179) 48 (2–189) 16 (2–160)
Day 6 postdose 34 (2–86) 52 (2–467) 45 (2–268) 39 (2–233) 2 (2–42)
TABLE 6. Numbers and percentages of subjects with two- or fourfold increases in antibody titers.
Titer increase seen
No. of subjects with indicated titer increase/no. tested (%) for group administered:
SB 209763 at dose of:
Placebo
10 mg/kg 5 mg/kg 1.25 mg/kg 0.25 mg/kg
Neutralization ratio
All subjects
.2-fold 5/11 (45) 5/11 (45) 3/9 (33) 2/7 (29) 1/10 (10)
.4-fold 4/11 (36) 4/11 (36) 2/9 (22) 2/7 (29) 1/10 (10)
Seronegative subjects, predose
.2-fold 3/3 (100) 2/2 (100) 2/2 (100) 2/2 (100) 1/2 (50)
.4-fold 3/3 (100) 2/2 (100) 2/2 (100) 2/2 (100) 1/2 (50)
Fusion ratio
All subjects
.2-fold 6/11 (55) 7/11 (64) 5/9 (56) 1/7 (14) 1/10 (10)
.4-fold 5/11 (45) 5/11 (45) 5/9 (56) 0/7 (0) 0/10 (0)
Seronegative subjects, predose
.2-fold 4/7 (57) 5/8 (63) 2/3 (67) 0/3 (0) 0/4 (0)
.4-fold 4/7 (57) 5/8 (63) 2/3 (67) 0/3 (0) 0/4 (0)
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who received single and multiple doses of SB 209763 and did
not develop a detectable anti-idiotypic reaction (4). Another
humanized RSV monoclonal antibody, directed against the F
protein, showed a similar lack of immunogenicity (16).
Although the number of sampling times in this study was
limited (n 5 7) in comparison to many studies examining
pharmacokinetics, sufficient information was available to pro-
vide individual values of Cmax and AUC0–t by utilizing non-
compartmental pharmacokinetic methods. However, parame-
ter estimates for AUC0–t and Cmax should be considered as
approximations of the values that would be obtained with a
more intensive sampling schedule. By the use of population
modeling, estimates of CL/F and VSS/F were obtainable. The
predicted CL/F of 0.143 (ml/h)/kg for the mean age of 298 days
is similar to values of intravenous clearance (CL) reported for
healthy adults who were administered intravenous doses of SB
209763 (15). In this earlier study, mean CL values ranged from
0.122 to 0.142 (ml/h)/kg for similar doses of 0.25 to 10.0 mg/kg.
Mean estimates for VSS/F from the earlier, intravenous
study of healthy adults ranged from 87.5 to 104 ml/kg for
doses of 0.25 to 10.0 mg/kg. This is in contrast to a mean
Vss/F of 161 ml/kg for the present study population. These
differences could be in part due to the larger proportion of
total and extracellular body water in infants and young chil-
dren (5).
Analysis of plasma neutralization and fusion inhibition an-
tibody levels following administration of a single dose of the
study medication suggests that doses of as little as 1.25 mg of
SB 209763 per kg may be associated with some increase in
antiviral activity. However, given the relatively low neutraliza-
tion and fusion inhibition antibody titers that were achieved
with the highest dosing regimen, it is not surprising that dif-
ferences in RSV attack rates were not observed. Also, the high
predose neutralization-antibody titer in placebo recipients may
have conferred some degree of protection, making it difficult to
detect a difference in RSV infection rates between groups.
Experience with a polyclonal, hyperimmune RSV globulin in-
dicates that serum neutralizing-antibody titers of greater than
1:200 are necessary to limit RSV replication in the lower re-
spiratory tract. Because of the presence of functionally distinct
populations among the RSV-neutralizing antibodies in a poly-
clonal antibody preparation, only a subset of neutralizing an-
tibodies may actually be protective (14). In this trial, the ab-
sence of a cumulative effect on antibody concentration that
would be derived from serial doses of SB 209763 also may have
contributed to the lack of an effect on RSV infection rates.
However, the lack of toxicity and the relative ease of i.m.
administration justify further consideration of RSV prophy-
laxis with a monoclonal antibody.
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